Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Spectrum Pharmaceuticals has signed an agreement to acquire licensing rights to market ZEVALIN (ibritumomab tiuxetan) injection for intravenous use outside of the US from Bayer Healthcare.
Subscribe to our email newsletter
As per the agreement, Spectrum will have all rights related to marketing, sales, and patents, and access to existing inventory of ZEVALIN from Bayer.
The Merchant Banking Group of Burrill & Company acted as advisor to Spectrum Pharmaceuticals in this transaction.
Spectrum will utilize a combination of company resources and partnerships to support the product outside the US, the company said.
ZEVALIN is approved for the treatment of follicular B-cell non-Hodgkin’s lymphoma, including countries in Europe, Latin America and Asia.
Spectrum chairman and CEO Rajesh Shrotriya said that with the licensing of ex-US, worldwide rights to ZEVALIN, they will be able to leverage their existing clinical, regulatory and marketing investments.
"Our access to the worldwide market will help patients with follicular lymphoma who can benefit from ZEVALIN," Shrotriya added.